Kang Zhel Pharmaceuticals (00867.HK): The innovative drug Sorafenib cream for AD indications in China's Phase III clinical trials has achieved positive results.

Wisdom Terminal Financial News APP: Kangzhe Pharmaceutical (00867.HK) announced that its subsidiary, Demei Pharmaceutical Co., Ltd. (specializing in innovative pharmaceutical enterprises focusing on skin health), is applying for independent listing on the main board of the Hong Kong Stock Exchange. They have obtained positive results from the Phase III clinical trial of phosphoaminolipidin cream for mild to moderate atopic dermatitis (AD) in China.